Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Chigenovo Co. Ltd. has 3 pending office actions in Biotechnology & Pharmaceuticals. The actions are distributed among 3 examiners and 3 art units, indicating that prosecution activity is spread across separate examination assignments rather than one centralized channel.
YU, DAVID TUYANG is the busiest examiner, with 1 pending matter. Since the busiest examiner is associated with only 1 action, counsel should maintain matter-specific tracking and avoid assuming that one examiner’s approach governs the full portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DAVID TUYANG | 1 | 100.0% | +0.0% |
| DUNN, LINDSAY MICHELLE | 1 | 80.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18360742 | USE OF CYP4V2 AND RDCVF IN THE MANUFACTURE OF MEDICAMENT | DUNN, LINDSAY MICHELLE | 26d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18571164 | PRPF31 VARIANT AND USES THEREOF | YU, DAVID TUYANG | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18571164 | PRPF31 VARIANT AND USES THEREOF | YU, DAVID TUYANG | 1635 | §103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18360742 | USE OF CYP4V2 AND RDCVF IN THE MANUFACTURE OF MEDICAMENT | DUNN, LINDSAY MICHELLE | 1644 | §103DP | Non-Final OA | 26d | Pending | Jul 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChigenovo Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
David Tuyang Yu has the most, with 1 of Chigenovo Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
